Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Clin. transl. oncol. (Print)
; 23(8): 1717-1726, ago. 2021.
Article
in En
| IBECS
| ID: ibc-222170
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Background and purpose Renal cell carcinoma (RCC) has traditionally been considered radioresistant with a limited role for conventional fractionation as a local approach. Nevertheless, since the appearance of stereotactic body radiation therapy (SBRT), radiotherapy (RT) has been increasingly employed in the management of metastatic RCC (mRCC). The aim of this study was to evaluate the role of SBRT for synchronous and metachronous oligo metastatic RCC patients in terms of local control, delay of systemic treatment, overall survival and toxicity. Patients and methods A Monocentric single institution retrospective data collection was performed. Inclusion criteria were (1) oligo-recurrent or oligo-progressive disease (less than 5 metastases) in mRCC patients after radical/partial nephrectomy or during systemic therapy, (2) metastasectomy or other metastasis-directed, rather than SBRT not feasible, (3) any contraindication to receive systemic therapy (such as comorbidities), (4) all the histologies were included, (5) available signed informed consent form for treatment. Tumor response and toxicity were evaluated using the response evaluation criteria in solid tumors and the Common Terminology Criteria for Adverse Events version 4.03, respectively. Progression-free survival in-field and out-field (in-field and out-field PFS) and overall survival (OS) were calculated via the KaplanMeier method. The drug treatment-free interval was calculated from the start of SBRT to the beginning of any systemic therapy. Results From 2010 to December 2018, 61 patients with extracranial and intracranial metastatic RCC underwent SBRT on 83 lesions. Intracranial and extracranial lesions were included. Forty-five (74%) patients were treated for a solitary metastatic lesion. Median RT dose was 25 Gy (range 1052) in 510 fractions. With a median follow-up of 2.3 years (range 07.15), 1-year in-field PFS was 70%, 2-year in-field PFS was 55% (AU)
Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Carcinoma, Renal Cell
/
Radiosurgery
/
Kidney Neoplasms
Limits:
Humans
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2021
Document type:
Article